mRNA Expression of FGFR1 as Potential Marker for Predicting Prognosis of Surgical Resection of Small Cell Lung Cancer may be better than Protein Expression and Gene Amplification
mRNA Expression of FGFR1 as Potential Marker for Predicting Prognosis of Surgical Resection of Small Cell Lung Cancer may be better than Protein Expression and Gene Amplification
复制标题
FGFR1 mRNA表达作为预测小细胞肺癌手术切除预后的潜在标志物可能优于蛋白表达和基因扩增
DOI：
10.7150/jca.44476
复制
发表时间：
2020-05
期刊：
影响因子：
--
通讯作者：
Hongyang Lu
中科院分区：
文献类型：
--
作者：
Jing Qin;Fajun Xie;Fenfang Wang;Hongyang Lu
目的：成纤维细胞生长因子受体1(FGFR1)在包括肺癌在内的多种癌症中均有表达，但其在小细胞肺癌(SCLC)中的作用尚未明确。本研究旨在明确中国人小细胞肺癌手术切除患者中FGFR1基因突变的频率，并探讨其与临床病理特征及预后的关系。方法：应用免疫组织化学(IHC)、荧光原位杂交(FISH)、聚合酶链式反应(PCR)和逆转录聚合酶链式反应(RT-PCR)分别检测33例小细胞肺癌原发灶中FGFR1蛋白表达、FGFR1扩增、FGFR1突变和信使RNA(MRNA)水平。结果：FGFR1蛋白表达阳性率为21.2%(7/33)。FGFR1扩增4例(14.3%)。若以3.5为界值，则7/33例(21.2%)为FGFR1mRNA阳性。而在33例小细胞肺癌术后组织标本中均未检测到突变。FGFR1蛋白表达或扩增与临床特征及预后无明显相关性。MRNA水平和预后不良的趋势明显，包括无复发生存期(RFS)(p=0.07)和总生存期(OS)(p=0.08)，但无统计学意义。结论：随着新的FGFR1靶向治疗方法的发展，FISH、IHC，尤其是mRNA的检测，可作为小细胞肺癌FGFR1通路失调的生物标志物。
Purpose: Fibroblast growth factor receptor 1 (FGFR1) alterations have been described in many cancers, including lung cancer, but the role has not been elucidated specifically in small cell lung cancer (SCLC). The present study aimed to identify the frequency of FGFR1 alterations among Chinese patients with surgically resected SCLC and the association with the clinicopathological characteristics and the survival were also investigated. Methods: FGFR1 protein expression, FGFR1 amplification, FGFR1 mutations, and messenger RNA (mRNA) levels, were determined by immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), polymerase chain reaction (PCR) and reverse transcription-polymerase chain reaction (RT-PCR), respectively in primary tumors from 33 patients with resected SCLC. Results: 7/33(21.2%) of the specimens were positive for FGFR1 protein expression. FGFR1 amplification was identified in 4/28 cases (14.3%). If the cut-off value was determined to be 3.5, FGFR1 mRNA positivity was considered in 7/33 cases (21.2%). However, no mutation was detected in the 33 SCLC postoperative tissue specimens. No significant association was observed between FGFR1 protein expression or amplification and clinicalcharacteristics or prognosis. There was a distinct trend for mRNA level and poor prognosis, including recurrence-free survival (RFS) (p = 0.07) and overall survival (OS) (p= 0.08), but they did not reach statistical significance. Conclusions: As novel FGFR1-targeted therapies are developed, FISH, IHC, especially mRNA were detected, which should be considered as biomarkers of FGFR1 pathway dysregulation in SCLC.
登录
查看更多内容
影响因子：
5.3
作者：
J. S. Park;Jaesang Lee;E. Y. Kim;J. Jung;S. K. Kim;Joon Chang;Dae Joon Kim;Chang Young Lee
通讯作者：
J. S. Park;Jaesang Lee;E. Y. Kim;J. Jung;S. K. Kim;Joon Chang;Dae Joon Kim;Chang Young Lee
DOI：
--
发表时间：
2016
期刊：
--
影响因子：
--
作者：
三好 智裕
通讯作者：
三好 智裕
DOI：
10.1016/j.jtho.2017.09.1951
发表时间：
2018-01
期刊：
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
影响因子：
--
作者：
Almodovar K;Iams WT;Meador CB;Zhao Z;York S;Horn L;Yan Y;Hernandez J;Chen H;Shyr Y;Lim LP;Raymond CK;Lovly CM
通讯作者：
Lovly CM
DOI：
10.1158/1078-0432.ccr-14-3357
发表时间：
2015-10-01
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Göke F;Franzen A;Hinz TK;Marek LA;Yoon P;Sharma R;Bode M;von Maessenhausen A;Lankat-Buttgereit B;Göke A;Golletz C;Kirsten R;Boehm D;Vogel W;Kleczko EK;Eagles JR;Hirsch FR;Van Bremen T;Bootz F;Schroeck A;Kim J;Tan AC;Jimeno A;Heasley LE;Perner S
通讯作者：
Perner S
影响因子：
8
作者：
Weeden, Clare E.;Ah-Cann, Casey;Asselin-Labat, Marie-Liesse
通讯作者：
Asselin-Labat, Marie-Liesse